Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Summarized Unaudited Financial Information for the Equity Method Investments

Summarized unaudited financial data as of March 31, 2016 and December 31, 2015 and for the three months ended March 31, 2016 and 2015, for the Company's equity method investments are shown in the following tables. Summarized unaudited financial data for ZIOPHARM Oncology, Inc. ("ZIOPHARM") has been included for the three months ended March 31, 2015 as the Company determined it had significant influence over ZIOPHARM until the Company distributed all of its equity securities held in ZIOPHARM to its shareholders in June 2015.

	March 31, 2016		December 31, 2015
Current assets	$	56,800	$	28,123
Non-current assets	10,672		1,539
Total assets	67,472		29,662
Current liabilities	7,592		6,274
Net assets	$	59,880	$	23,388

	Three Months Ended   March 31,
	2016			2015
Revenues	$	282		$	636
Operating expenses	17,660			84,069
Operating loss	(17,378		)	(83,433		)
Other	3			(1		)
Net loss	$	(17,375	)	$	(83,434	)